Cardiovascular Toxicities Associated With Immune Checkpoint Inhibitors: Clinical Phenotypes, Mechanisms, Diagnosis, and Management-A Narrative Review. (PubMed, Crit Rev Oncol Hematol) - Oct 17, 2026 - "Management should combine early recognition, careful exclusion of competing diagnoses, and coordinated oncology-cardiology decision-making. Current evidence does not justify uniform screening thresholds or a standard rescue regimen, and investigational biomarkers, imaging probes, and targeted immunomodulators require prospective validation."
Checkpoint inhibition • IO biomarker • Journal • Atherosclerosis • Cardiovascular • Heart Failure • Inflammation • Oncology
|
|
Jieyi Yang; Jilu Lang; Shuhong Wu; Wei-Jan Wang; Xian Sun; Xiaoman Wang
|